Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City

Autor: Matthew J. Lewis, Brett R. Anderson, Michael Fremed, Melissa Argenio, Usha Krishnan, Rachel Weller, Stéphanie Levasseur, Robert Sommer, Irene D. Lytrivi, Emile A. Bacha, Julie Vincent, Wendy K. Chung, Erika B. Rosenzweig, Thomas J. Starc, Marlon Rosenbaum, Oliver Barry, Tarif Choudhary, Eva Cheung, Kanwal Farooqi, Anne Ferris, David Kalfa, Ganga Krishnamurthy, Damien LaPar, Leo Liberman, Diane Rhee, Amee Shah, Eric Silver, Sangee Suh, Joyce Woo
Rok vydání: 2020
Předmět:
Adult
Heart Defects
Congenital
Male
Pediatrics
medicine.medical_specialty
Complications
Coronavirus disease 2019 (COVID-19)
Heart disease
Columbia university
030204 cardiovascular system & hematology
Azithromycin
outcomes
Severity of Illness Index
Cohort Studies
03 medical and health sciences
Young Adult
0302 clinical medicine
COVID‐19
Clinical endpoint
Intubation
Intratracheal
adult congenital heart disease
Medicine
Humans
030212 general & internal medicine
Stage (cooking)
Aged
Retrospective Studies
Original Research
Academic Medical Centers
business.industry
Genetic Diseases
Inborn
Oxygen Inhalation Therapy
Congenital Heart Disease
COVID-19
Odds ratio
medicine.disease
Pulmonary hypertension
Hospitalization
Cohort
Female
New York City
Mortality/Survival
Cardiology and Cardiovascular Medicine
business
Hydroxychloroquine
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
ISSN: 2047-9980
Popis: Background We sought to assess the impact and predictors of coronavirus disease 2019 (COVID‐19) infection and severity in a cohort of patients with congenital heart disease (CHD) at a large CHD center in New York City. Methods and Results We performed a retrospective review of all individuals with CHD followed at Columbia University Irving Medical Center who were diagnosed with COVID‐19 between March 1, 2020 and July 1, 2020. The primary end point was moderate/severe response to COVID‐19 infection defined as (1) death during COVID‐19 infection; or (2) need for hospitalization and/or respiratory support secondary to COVID‐19 infection. Among 53 COVID‐19‐positive patients with CHD, 10 (19%) were P =0.0002), and in adults, physiological Stage C or D (OR, 19.38; P =0.002) were significantly associated with moderate/severe infection. Conclusions At our CHD center, the number of symptomatic patients with COVID‐19 was relatively low. Patients with CHD with a genetic syndrome and adults at advanced physiological stage were at highest risk for moderate/severe infection.
Databáze: OpenAIRE
Externí odkaz: